Celloram and collaborators described PROTEXI, a dendritic-cell vaccine concept that repurposes immune memory generated by SARS-CoV-2 infection and vaccination to drive anti-tumor responses. Published in Nature Communications, the approach reframes cancer vaccine design around redirecting existing antiviral helper T-cell activity instead of building entirely new immune targets, aiming to improve both practicality and potency of vaccination strategies.